Society of Nuclear Medicine--57th annual meeting.
The 57th Annual Meeting of the Society of Nuclear Medicine, held in Salt Lake City, UT, USA, included topics covering new developments in imaging agents and radiopharmaceutical therapies in the field of nuclear medicine. This conference report highlights selected presentations related to imaging of the brain, the prediction of heart disease, and the detection and treatment of various cancers. Investigational drugs discussed include TF-2 plus [68Ga]IMP-288 and TF-2 plus [111In]IMP-288 (both Immunomedics Inc), [11C]PBR-170 (Royal Prince Alfred Hospital/Australian Nuclear Science & Technology Organization), [11C]LY-2795050 (Eli Lilly & Co), yttrium (90Y) clivatuzumab tetraxetan (Garden State Cancer Center/Immunomedics Inc), [18F]LMI-1195 (Lantheus Medical Imaging Inc), fluciclovine (18F) (GE Healthcare/Nihon Medi-Physics Co Ltd), [99mTc]MIP-1340 and [99mTc]MIP-1407 (both Molecular Insight Pharmaceuticals Inc).
Searle
Ben
B
Thomson Reuters, London, UK. ben.searle@thomsonreuters.com
D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006331:Heart Diseases / Q000000981:diagnostic imaging; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D015507:Drugs, Investigational; D019275:Radiopharmaceuticals